samedan logo
 
 
 
spacer
home > pmps > spring 2009 > keeping cool under extreme conditions
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Keeping Cool Under Extreme Conditions

Amid all the merger and acquisition activity that seems to be holding the headlines in the pharmaceutical and healthcare sectors, it is easy to miss an important point. A key feature of the industry’s future success and growth will rest on the next two to three years, when over 50 per cent of all newly approved medicines will be biopharmaceuticals (1).

Why is that so important? With over 65 per cent of biopharmaceutical products and almost all vaccines being highly temperature-sensitive, their market success is completely dependent upon the ability to protect them from extremes outside their specified storage and transportation range during shipping. Exposure to temperature extremes can render biological drugs less effective, change their potency, and affect patient safety.

As if maintaining product efficacy isn’t enough of a challenge, consider the rapid growth of contract manufacturing organisations (CMOs) and the impact this could potentially have on the distance between point of manufacture, processing and final sale. Many of the world’s CMO sites are located in regions where the local transportation infrastructure often presents a significant challenge.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Jonathan Neeld has more than 22 years’ experience in air transportation and mechanical engineering. He has worked at AmSafe Bridport, one of the world’s largest commercial air cargo equipment manufacturers, since 1997 and has recently joined the newly formed CSafe company as Engineering & Certification Manager. He has been active with many of the technical committees involved with the safe transportation of air cargo, including the IATA ULD Technical Panel and the SAE Cargo Handling subcommittee.
spacer
Jonathan Neeld
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

EUROPEAN CHMP ADOPTS POSITIVE OPINION FOR KITE’S KTE-X19 FOR THE TREATMENT OF RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA

-- If Approved, KTE-X19 will be an Important New Advance for this Disease with a Poor Prognosis -- -- Kite would Become the First Company with Multiple Approved CAR T Therapies in Europe --
More info >>

White Papers

Clinical Trials in Emerging Markets: Goldmines or Landmines?

Pharm-Olam, LLC

Over the past decade, biopharmaceutical companies have increasingly turned to emerging markets as a way to reduce clinical trial costs and timelines. Areas such as Eastern Europe, India, and Latin America—with their ready population of treatment naïve patients—can be an answer to the intense competition for patients seen in developed markets. Many of the countries within these regions may now be considered as “emerged” countries but yet, conducting trials in these regions does require some special attention and expertise. Before deciding to conduct studies in these areas, companies should have a full appreciation for the ethical, medical, regulatory, legal, and operational hurdles that must be surmounted for success. Here we highlight a number of those issues and offer our recommendations for how sponsor companies can deal with them effectively.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement